DEVELOPMENT AND VALIDATION OF A BIOANALYTICAL METHOD FOR THERAPEUTIC DRUG MONITORING OF AMIKACIN IN HUMAN PLASMA USING ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY

Triswanto Sentat, Henny Lucida, Widyati Widyati, Hansen Nasif, Yahdiana Harahap, Pandu Harijono, Ratih Ratih

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The primary purposes of this research were to develop and validate a novel, accurate, sensitive, and repeatable bioanalytical method for determining amikacin in human plasma employing UPLC-MS/MS. Methods: The bioanalytical procedure of amikacin involved a BEH C18 UPLC column as a stationary phase, with an employed mobile phase consisting of 0.1% v/v formic acid and acetonitrile (85:15 v/v). The flow rate was set at 0.1 ml/min, and the column temperature was kept at 30 °C. Kanamycin was selected as an internal standard. Amikacin and kanamycin were determined at mass-to-charge ratios (m/z) of 585.9>162.9 and 484.67>162.83, respectively. The amikacin bioanalysis method in the plasma matrix at the optimum separation condition was validated by determination of selectivity, linearity, accuracy, precision, recovery, carry-over, matrix effect, and stability. Results: The optimum conditions of the sample preparation procedure were obtained through liquid-liquid extraction using trichloroacetic acid, followed by vortex mixing for one minute and centrifugation at 10,000 rpm for five minutes. Ten µl of supernatant was collected and injected into the system. A linear response was achieved in the 1.0-150.0 µg/ml range with R2 0.9997. Accuracy and precision met the requirements with % differences and coefficient variation at all concentration levels less than 15% and at the LLOQ level (1 μg/ml) less than 20%. The validated analytical method of amikacin in plasma is required for therapeutic monitoring in patients. The data would be valuable for determining or adjusting amikacin doses to enhance patient safety. Conclusion: A bioanalytical method was developed and validated for determining amikacin in human plasma by UPLC-MS/MS. The method selectivity, linearity, accuracy, precision, recovery, carry-over, matrix effect, and stability were performed.

Original languageEnglish
Pages (from-to)140-144
Number of pages5
JournalInternational Journal of Applied Pharmaceutics
Volume16
Issue numberSpecial Issue 1
DOIs
Publication statusPublished - Feb 2024

Keywords

  • Amikacin
  • Bioanalytical method
  • Human plasma
  • Kanamycin
  • Therapeutic drug monitoring
  • UPLC-MS/MS
  • Validation

Fingerprint

Dive into the research topics of 'DEVELOPMENT AND VALIDATION OF A BIOANALYTICAL METHOD FOR THERAPEUTIC DRUG MONITORING OF AMIKACIN IN HUMAN PLASMA USING ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY'. Together they form a unique fingerprint.

Cite this